v3.26.1
Significant agreements - Bayer Collaboration Agreement (Details)
$ in Thousands, £ in Millions
1 Months Ended 12 Months Ended
May 04, 2023
USD ($)
item
Nov. 30, 2025
USD ($)
Program
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
May 04, 2023
GBP (£)
item
Significant agreements.            
Revenue from collaborative arrangement     $ 72,586 $ 35,275 $ 26,976  
Deferred revenue     38,469 101,658 135,194  
Bayer Collaboration Agreement            
Significant agreements.            
Number of collaboration targets | item 2         2
Revenue from collaborative arrangement   $ 5,500 8,920 3,393 1,160  
Deferred revenue     $ 34,629 $ 39,960 $ 43,618  
Material rights exercise period 7 years          
Milestone payments, receivable | £           £ 583.5
Expected period for satisfaction of performance obligations 2 years          
Estimated amount payable to CROs $ 2,500          
Number of research programs | Program   1        
Payment received $ 45,000          
Bayer Collaboration Agreement | Minimum            
Significant agreements.            
Number of candidate compounds into further development | item 1         1
Bayer Collaboration Agreement | Maximum            
Significant agreements.            
Number of collaboration targets | item 3         3
Milestone payments receivable | £           £ 194.5
Bayer Collaboration Agreement | Development and regulatory milestones | Maximum            
Significant agreements.            
Milestone payments receivable | £           178.3
Bayer Collaboration Agreement | Across all three potential target programs            
Significant agreements.            
Milestone payments receivable | £           £ 534.9